Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT.
- Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT.
- The medicinal potential of CBD has been established; however, because it is poorly absorbed there have been challenges related to the oral administration of CBD.
- Cocrystals are solid compositions designed to improve the physical characteristics of a drug, which can produce pharmaceutical, regulatory, and manufacturing advantages.
- “We are excited to share new, positive research results from our ongoing preclinical development program with ART12.11,” said Gregory D. Gorgas, President and Chief Executive Officer at Artelo.